NCT03811912View on ClinicalTrials.gov

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

November 21, 2019

Study Completion Date

November 21, 2019

Conditions
Alopecia Areata
Interventions
DRUG

CTP-543

CTP-543 administered as 8 mg tablet.

DRUG

CTP-543 Matching Placebo

Administered as tablets to aid treatment masking.

Trial Locations (10)

27104

Investigative Site, Winston-Salem

33472

Investigative Site, Boynton Beach

55432

Investigative Site, Fridley

92697

Investigative Site, Irvine

94118

Investigative Site, San Francisco

97210

Investigative Site, Portland

06519

Investigative Site, New Haven

02114

Investigative Site, Boston

02115

Investigative Site, Boston

03801

Investigative Site, Portsmouth

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY